🕒 Last update: loading…21/11/2026

Stock Cytosorbents Corporation CTSO

Cytosorbents Corporation — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -52.35%

Price change 2019 → 2020: 107.01%

Price change 2020 → 2021: -47.43%

Price change 2021 → 2022: -63.01%

Price change 2022 → 2023: -28.39%

Price change 2023 → 2024: -18.02%

Price change 2024 → 2025: -29.76%

Price change 2025 → 2026: 636.86%

Price change 2026 (year to date): 618.21%

Financial growth

Revenue CAGR (8 years): 9.02%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 4.93

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -16.68

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 38.67% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Cytosorbents Corporation–4.93–🔒
Aelis Farma S.A.–1.49+49.1 %–
Biosynex S.A.–1.90+35.4 %–
Geratherm Medical AG–0.13−1.2 %–
Femasys Inc.–0.80+16.2 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Cytosorbents Corporation over the latest fiscal years.

Revenue
37.1 m USD
fiscal year 2025
Net income
-8.2 m USD
fiscal year 2025
Net margin
-22.1 %
fiscal year 2025
Average annual growth
-1.2 %
Revenue growth over 5 years
Average annual growth
+24.8 %
Revenue growth over 10 years
Market cap
15.3 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202039.5 m-7.8 m-19.9 %n/a
202140.1 m-24.6 m-61.2 %+1.7 %
202234.7 m-32.8 m-94.6 %-13.5 %
202331.1 m-29.2 m-94.1 %-10.4 %
202435.6 m-20.7 m-58.2 %+14.5 %
202537.1 m-8.2 m-22.1 %+4.1 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Cytosorbents Corporation over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-12.53
risk zone (below 1.81)
Piotroski Score
4 / 9
4 to 6: average accounts
Net Debt / EBITDA
-2.11 x
net cash
Fiscal year20212022202320242025
Cash and investments52.1 m22.1 m14.1 m3.3 m6.2 m
Total Debt13.8 m18.3 m18.3 m26.9 m29.1 m
Net Debt-38.3 m-3.9 m4.2 m23.6 m22.9 m
Equity62.6 m35.4 m23.3 m11.1 m5.9 m
Total assets89.5 m63.2 m53.3 m47.4 m44.2 m
Operating cash flow-14.0 m-28.2 m-21.7 m-14.4 m-12.4 m
Investments (capex)4.3 m6.5 m936,236669,430164,000
Free cash-flow-18.3 m-34.7 m-22.6 m-14.7 m-12.5 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.96 x
Price / book value-6.99 x
Return on Equity (ROE)-1,340.0 %
Return on Invested Capital (ROIC)-39.3 %
Net margin-45.0 %
Debt / equity-12.81 x
Current ratio0.55 x
Interest coverage-6.50 x
Free cash-flow yield-50.2 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Cytosorbents Corporation compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Cytosorbents Corporation15.3 mn/a-22.1 %
IceCure Medical Ltd ICCM1.6 mn/a-445.6 %
TELA Bio, Inc. TELA37.1 mn/a-48.4 %
Spectral AI, Inc. MDAI41.8 mn/a-38.5 %
Sensus Healthcare, Inc. SRTS38.3 mn/a-28.1 %
NeuroOne Medical Technologies Corporation NMTC6.8 mn/a-29.8 %
Baird Medical Investment Holdings Limited BDMD2.9 mn/a-121.0 %
electroCore, Inc. ECOR48.4 mn/a-43.6 %
Telomir Pharmaceuticals, Inc. Common Stock TELO36.1 mn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Cytosorbents Corporation publish: ratings, price targets and earnings forecasts.

Majority rating
buy
13 analysts

Breakdown of ratings

strong buy 0buy 12hold 1sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Cytosorbents Corporation: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
12/11/2026-0.58-0.90n/a
06/08/2026-1.40-0.80n/a
13/05/2026-0.08-0.06n/a
25/03/2026-0.09-1.00n/a
13/11/2025-0.04-1.20n/a
07/08/2025-0.05-0.07n/a

Stock splits

DateOperation
08/09/2026reverse split: 1 share for 20
05/12/2014reverse split: 1 share for 25

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Cytosorbents Corporation.

Free float
86.0 %
share of freely traded shares
Large funds tracked
10
hold the stock as of 2026Q2
Executives (insiders)
6 / 0
6 purchases, 0 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group2.2 m1.4 m0.0 %0.0 %2025Q4
BlackRock627,211234,5770.0 %-19.9 %2026Q2
Geode Capital Management602,059225,2390.0 %-14.9 %2026Q2
State Street318,586119,1520.0 %+100.0 %2026Q2
Northern Trust111,66041,7610.0 %+20.7 %2026Q2
Renaissance Technologies100,02037,4070.0 %-0.7 %2026Q2
Morgan Stanley91,33834,1600.0 %-8.8 %2026Q2
Bank of America38,68614,4680.0 %-1.1 %2026Q2

Latest insider transactions

DatePersonSideAmount
15/09/2026Chan Phillip P.purchase22,644 USD
15/09/2026Sobel Alan D.purchase11,628 USD
15/09/2026Sobel Alan D.purchase3,025 USD
15/09/2026Sobel Alan D.purchase601 USD
14/09/2026Capponi Vincentpurchase10,926 USD
14/09/2026Capponi Vincentpurchase1,611 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 08/08/2006
ISIN code
US23283X2062
Workforce
149
full-time employees
Chief executive
Phillip P. Chan

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Cytosorbents Corporation

What is the Cytosorbents Corporation share price?

Latest recorded price: 4.87 USD on 13/11/2026, for a market cap of 15.3 m USD.

What is the revenue of Cytosorbents Corporation?

37.1 m USD for fiscal year 2025, with net income of -8.2 m USD (net margin -22.1 %).

What do analysts say about Cytosorbents Corporation?

Out of 13 analysts: 12 buy or strong buy, 1 hold, 0 sell or strong sell.

Is Cytosorbents Corporation stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US23283X2062).

How many employees does Cytosorbents Corporation have?

149 full-time employees according to the latest published profile.

Who runs Cytosorbents Corporation?

Phillip P. Chan is the company's chief executive.

Which large funds own Cytosorbents Corporation?

As of 2026Q2, among the large funds tracked: Vanguard Group, BlackRock, Geode Capital Management, State Street, Northern Trust.

07

Similar stocks